Search

Your search keyword '"Lazzaro, Antonio"' showing total 214 results
Start Over Author "Lazzaro, Antonio"
214 results on '"Lazzaro, Antonio"'

1. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Author

Schjesvold, Fredrik, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Nikolayeva, Anna, Tomczak, Waldemar, Pour, Ludek, Spicka, Ivan, Dimopoulos, Meletios-Athanasios, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Maisnar, Vladimir, Mikala, Gabor, Rosinol, Laura, Konstantinova, Tatiana, Lazzaro, Antonio, Liberati, Anna Marina, Symeonidis, Anargyros, Gatt, Moshe, Illes, Arpad, Abdulhaq, Haifaa, Dungarwalla, Moez, Grosicki, Sebastian, Hajek, Roman, Leleu, Xavier, Myasnikov, Alexander, Richardson, Paul G., Avivi, Irit, Deeren, Dries, Gironella, Mercedes, Hernandez-Garcia, Miguel Teodoro, Martinez Lopez, Joaquin, Newinger-Porte, Muriel, Ribas, Paz, Samoilova, Olga, Voog, Eric, Arnao-Herraiz, Mario, Carrillo-Cruz, Estrella, Corradini, Paolo, Dodlapati, Jyothi, Granell Gorrochategui, Miquel, Huang, Shang-Yi, Jenner, Matthew, Karlin, Lionel, Kim, Jin Seok, Kopacz, Agnieszka, Medvedeva, Nadezhda, Min, Chang-Ki, Mina, Roberto, Palk, Katrin, Shin, Ho-Jin, Sohn, Sang Kyun, Sonneveld, Pieter, Tache, Jason, Anagnostopoulos, Achilles, Arguiñano, Jose-Maria, Cavo, Michele, Filicko, Joanne, Garnes, Margaret, Halka, Janusz, Herzog-Tzarfati, Kathrin, Ipatova, Natalia, Kim, Kihyun, Krauth, Maria-Theresa, Kryuchkova, Irina, Lazaroiu, Mihaela Cornelia, Luppi, Mario, Proydakov, Andrei, Rambaldi, Alessandro, Rudzianskiene, Milda, Yeh, Su-Peng, Alcalá-Peña, Maria Magdalena, Alegre Amor, Adrian, Alizadeh, Hussain, Bendandi, Maurizio, Brearton, Gillian, Brown, Randall, Cavet, Jim, Dally, Najib, Egyed, Miklos, Hernández-Rivas, José Ángel, Kaare, Ain, Karsenti, Jean-Michel, Kloczko, Janusz, Kreisle, William, Lee, Je-Jung, Legiec, Wojciech, Machherndl-Spandl, Sigrid, Manda, Sudhir, Mateos, Maria-Victoria, Moiseev, Ivan, Moreb, Jan, Nagy, Zsolt, Nair, Santosh, Oriol-Rocafiguera, Albert, Osswald, Michael, Otero-Rodriguez, Paula, Peceliunas, Valdas, Plesner, Torben, Rey, Philippe, Rossi, Giuseppe, Stevens, Don, Suriu, Celia, Tarella, Corrado, Verlinden, Anke, Zannetti, Alain, Schjesvold, Fredrik H, Pour, Luděk, Špička, Ivan, Mikala, Gábor, Rosiñol, Laura, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, and Richardson, Paul G

Published
2022
Full Text
View/download PDF

2. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Cavo, Michele, Fanin, Renato, Foa', Roberto, Rambaldi, Alessandro, Di Raimondo, Francesco, Rossi, Giuseppe, Boccadoro, Mario, Leoni, Pietro, Corradini, Paolo, Torelli, Giuseppe, Fioritoni, Giuseppe, Cortelazzo, Sergio, Lambertenghi Deliliers, Giorgio, La Nasa, Giorgio, Zaccaria, Alfonso, De Fabritiis, Paolo, Cascavilla, Nicola, Bosi, Alberto, Semenzato, Gianpietro, Gugliotta, Luigi, Gherlinzoni, Filippo, Angelucci, Emanuele, Martelli, Massimo Fabrizio, Petti, Maria Concetta, Leone, Giuseppe, Carella, Angelo Michele, Ciceri, Fabio, Santoro, Armando, Ferrara, Felicetto, Nobile, Francesco, D'Arco, Alfonso Maria, Levis, Alessandro, Guardigni, Luciano, Gallamini, Andrea, Musto, Pellegrino, Fattori, Pier Paolo, Galieni, Piero, Morandi, Sergio, Amadori, Dino, Gobbi, Marco, Rotoli, Bruno, Mirto, Salvatore, Lazzaro, Antonio, Paladini, Giorgio, Mozzana, Ruggero, Pinotti, Graziella, Rodeghiero, Francesco, Cantore, Nicola, Pavone, Vincenzo, Pogliani, Enrico Maria, Liberati, Anna Marina, Majolino, Ignazio, Amadori, Sergio, Lauria, Francesco, Aglietta, Massimo, Quarta, Giovanni, Storti, Sergio, Morabito, Fortunato, Capalbo, Silvana Franca, Gianni, Alessandro Massimo, Mettivier, Vincenzo, Rizzoli, Vittorio, Bernasconi, Carlo, Visani, Giuseppe, Pizzuti, Michele, La Verde, Giacinto, Avvisati, Giuseppe, Longinotti, Maurizio, Gallo, Eugenio, Dammacco, Franco, Russo, Domenico, Bacigalupo, Andrea, Musolino, Caterina, Tacchetti, Paola, Pantani, Lucia, Patriarca, Francesca, Petrucci, Maria Teresa, Zamagni, Elena, Dozza, Luca, Galli, Monica, Crippa, Claudia, Barbato, Simona, Tosi, Patrizia, Narni, Franco, Montefusco, Vittorio, Testoni, Nicoletta, Spadano, Antonio, Terragna, Carolina, Pescosta, Norbert, Marzocchi, Giulia, Cellini, Claudia, Ronconi, Sonia, Catalano, Lucio, De Sabbata, Giovanni, Cangialosi, Clotilde, Ciambelli, Fabrizio, and Elice, Francesca

Published
2020
Full Text
View/download PDF

3. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms

Author

Fraticelli, Sara, primary, Lucioni, Marco, additional, Neri, Giuseppe, additional, Marchiori, Deborah, additional, Cristinelli, Caterina, additional, Merli, Michele, additional, Monaco, Rodolfo, additional, Borra, Tiziana, additional, Lazzaro, Antonio, additional, Uccella, Silvia, additional, Arcaini, Luca, additional, and Paulli, Marco, additional

Published
2023
Full Text
View/download PDF

6. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Author

Schjesvold, Fredrik H. Dimopoulos, Meletios-Athanasios and Delimpasi, Sosana Robak, Pawel Coriu, Daniel Legiec, Wojciech Pour, Ludek Spicka, Ivan Masszi, Tamas Doronin, Vadim Minarik, Jiri Salogub, Galina Alekseeva, Yulia and Lazzaro, Antonio Maisnar, Vladimir Mikala, Gabor Rosinol, Laura Liberati, Anna Marina Symeonidis, Argiris Moody, Victoria Thuresson, Marcus Byrne, Catriona Harmenberg, Johan and Bakker, Nicolaas A. Hajek, Roman Mateos, Maria-Victoria and Richardson, Paul G. Sonneveld, Pieter OCEAN OP-103 Investigators

Abstract

Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provide a progression-free survival benefit compared with pomalidomide plus dexamethasone in patients with previously treated multiple myeloma. Methods In this randomised, open-label, head-to-head, phase 3 study (OCEAN), adult patients (aged >= 18 years) were recruited from 108 university hospitals, specialist hospitals, and community-based centres in 21 countries across Europe, North America, and Asia. Eligible patients had an ECOG performance status of 0-2; must have had relapsed or refractory multiple myeloma, refractory to lenalidomide (within 18 months of randomisation) and to the last line of therapy; and have received two to four previous lines of therapy (including lenalidomide and a proteasome inhibitor). Patients were randomly assigned (1:1), stratified by age, number of previous lines of therapy, and International Staging System score, to either 28-day cycles of melflufen and dexamethasone (melflufen group) or pomalidomide and dexamethasone (pomalidomide group). All patients received dexamethasone 40 mg orally on days 1, 8, 15, and 22 of each cycle. In the melflufen group, patients received melflufen 40 mg intravenously over 30 min on day 1 of each cycle and in the pomalidomide group, patients received pomalidomide 4 mg orally daily on days 1 to 21 of each cycle. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat (ITT) population. Safety was assessed in patients who received at least one dose of study medication. This study is registered with ClinicalTrials.gov, NCT03151811, and is ongoing. Findings Between June 12, 2017, and Sept 3, 2020, 246 patients were randomly assigned to the melflufen group (median age 68 years [IQR 60-72]; 107 [43%] were female) and 249 to the pomalidomide group (median age 68 years [IQR 61-72]; 109 [44%] were female). 474 patients received at least one dose of study drug (melflufen group n=228; pomalidomide group n=246; safety population). Data cutoff was Feb 3, 2021. Median progression-free survival was 6middot8 months (95% CI 5middot0-8middot5; 165 [67%] of 246 patients had an event) in the melflufen group and 4middot9 months (4middot2-5middot7; 190 [76%] of 249 patients had an event) in the pomalidomide group (hazard ratio [HR] 0middot79, [95% CI 0middot64-0middot98]; p=0middot032), at a median follow-up of 15middot5 months (IQR 9middot4-22middot8) in the melflufen group and 16middot3 months (10middot1-23middot2) in the pomalidomide group. Median overall survival was 19middot8 months (95% CI 15middot1-25middot6) at a median follow-up of 19middot8 months (IQR 12middot0-25middot0) in the melflufen group and 25middot0 months (95% CI 18middot1-31middot9) in the pomalidomide group at a median follow-up of 18middot6 months (IQR 11middot8-23middot7; HR 1middot10 [95% CI 0middot85-1middot44]; p=0middot47). The most common grade 3 or 4 treatment-emergent adverse events were thrombocytopenia (143 [63%] of 228 in the melflufen group vs 26 [11%] of 246 in the pomalidomide group), neutropenia (123 [54%] vs 102 [41%]), and anaemia (97 [43%] vs 44 [18%]). Serious treatment-emergent adverse events occurred in 95 (42%) patients in the melflufen group and 113 (46%) in the pomalidomide group, the most common of which were pneumonia (13 [6%] vs 21 [9%]), COVID-19 pneumonia (11 [5%] vs nine [4%]), and thrombocytopenia (nine [4%] vs three [1%]). 27 [12%] patients in the melflufen group and 32 [13%] in the pomalidomide group had fatal treatment-emergent adverse events. Fatal treatment-emergent adverse events were considered possibly treatment related in two patients in the melflufen group (one with acute myeloid leukaemia, one with pancytopenia and acute cardiac failure) and four patients in the pomalidomide group (two patients with pneumonia, one with myelodysplastic syndromes, one with COVID-19 pneumonia). Interpretation Melflufen plus dexamethasone showed superior progression-free survival than pomalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Funding Oncopeptides AB Copyright (c) 2022 Elsevier Ltd. All rights reserved.

Published
2022

9. OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses

Author

Richardson, Paul G., primary, Schjesvold, Fredrik H., additional, Abdulhaq, Haifaa, additional, Coriu, Daniel, additional, Lazzaro, Antonio, additional, Sonneveld, Pieter, additional, Kullenburg, Torbjörn, additional, Harmenberg, Johan, additional, Thuresson, Marcus, additional, Byrne, Catriona, additional, and Mateos, María-Victoria, additional

Published
2021
Full Text
View/download PDF

10. OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Author

Schjesvold, Fredrik, primary, Dimopoulos, Meletios-Athanasios, additional, Delimpasi, Sosana, additional, Robak, Pawef, additional, Coriu, Daniel, additional, Legiec, Wojciech, additional, Pour, Luděk, additional, Špička, Ivan, additional, Masszi, Tamás, additional, Doronin, Vadim, additional, Minarik, Jiri, additional, Salogub, Galina, additional, Alexeeva, Yulia, additional, Lazzaro, Antonio, additional, Maisnar, Vladimir, additional, Mikala, Gábor, additional, Moody, Victoria, additional, Thuresson, Marcus, additional, Byrne, Catriona, additional, Harmenberg, Johan, additional, Hájek, Roman, additional, Mateos, María-Victoria, additional, Richardson, Paul G., additional, and Sonneveld, Pieter, additional

Published
2021
Full Text
View/download PDF

12. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study

Author

Tacchetti, Paola, Terragna, Carolina, Galli, Monica, Zamagni, Elena, Petrucci, Maria Teresa, Pezzi, Annalisa, Montefusco, Vittorio, Martello, Marina, Tosi, Patrizia, Baldini, Luca, Peccatori, Jacopo, Ruggieri, Miriana, Pantani, Lucia, Lazzaro, Antonio, Elice, Francesca, Rocchi, Serena, Gozzetti, Alessandro, Cavaletti, Guido, Palumbo, Antonio, and Cavo, Michele

Published
2014
Full Text
View/download PDF

16. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Author

Tacchetti, Paola, primary, Pantani, Lucia, additional, Patriarca, Francesca, additional, Petrucci, Maria Teresa, additional, Zamagni, Elena, additional, Dozza, Luca, additional, Galli, Monica, additional, Di Raimondo, Francesco, additional, Crippa, Claudia, additional, Boccadoro, Mario, additional, Barbato, Simona, additional, Tosi, Patrizia, additional, Narni, Franco, additional, Montefusco, Vittorio, additional, Testoni, Nicoletta, additional, Spadano, Antonio, additional, Terragna, Carolina, additional, Pescosta, Norbert, additional, Marzocchi, Giulia, additional, Cellini, Claudia, additional, Galieni, Piero, additional, Ronconi, Sonia, additional, Gobbi, Marco, additional, Catalano, Lucio, additional, Lazzaro, Antonio, additional, De Sabbata, Giovanni, additional, Cangialosi, Clotilde, additional, Ciambelli, Fabrizio, additional, Musto, Pellegrino, additional, Elice, Francesca, additional, Cavo, Michele, additional, Fanin, Renato, additional, Foa', Roberto, additional, Rambaldi, Alessandro, additional, Rossi, Giuseppe, additional, Leoni, Pietro, additional, Corradini, Paolo, additional, Torelli, Giuseppe, additional, Fioritoni, Giuseppe, additional, Cortelazzo, Sergio, additional, Lambertenghi Deliliers, Giorgio, additional, La Nasa, Giorgio, additional, Zaccaria, Alfonso, additional, De Fabritiis, Paolo, additional, Cascavilla, Nicola, additional, Bosi, Alberto, additional, Semenzato, Gianpietro, additional, Gugliotta, Luigi, additional, Gherlinzoni, Filippo, additional, Angelucci, Emanuele, additional, Martelli, Massimo Fabrizio, additional, Petti, Maria Concetta, additional, Leone, Giuseppe, additional, Carella, Angelo Michele, additional, Ciceri, Fabio, additional, Santoro, Armando, additional, Ferrara, Felicetto, additional, Nobile, Francesco, additional, D'Arco, Alfonso Maria, additional, Levis, Alessandro, additional, Guardigni, Luciano, additional, Gallamini, Andrea, additional, Fattori, Pier Paolo, additional, Morandi, Sergio, additional, Amadori, Dino, additional, Rotoli, Bruno, additional, Mirto, Salvatore, additional, Paladini, Giorgio, additional, Mozzana, Ruggero, additional, Pinotti, Graziella, additional, Rodeghiero, Francesco, additional, Cantore, Nicola, additional, Pavone, Vincenzo, additional, Pogliani, Enrico Maria, additional, Liberati, Anna Marina, additional, Majolino, Ignazio, additional, Amadori, Sergio, additional, Lauria, Francesco, additional, Aglietta, Massimo, additional, Quarta, Giovanni, additional, Storti, Sergio, additional, Morabito, Fortunato, additional, Capalbo, Silvana Franca, additional, Gianni, Alessandro Massimo, additional, Mettivier, Vincenzo, additional, Rizzoli, Vittorio, additional, Bernasconi, Carlo, additional, Visani, Giuseppe, additional, Pizzuti, Michele, additional, La Verde, Giacinto, additional, Avvisati, Giuseppe, additional, Longinotti, Maurizio, additional, Gallo, Eugenio, additional, Dammacco, Franco, additional, Russo, Domenico, additional, Bacigalupo, Andrea, additional, and Musolino, Caterina, additional

Published
2020
Full Text
View/download PDF

23. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi

Author

Morabito, Fortunato, Gallamini, Andrea, Stelitano, Caterina, Callea, Vincenzo, Guglielmi, Cesare, Neri, Santo, Lazzaro, Antonio, Orsucci, Lorella, Ilariucci, Fiorella, Sacchi, Stefano, Vitolo, Umberto, and Federico, Massimo

Subjects
T cells -- Comparative analysis, T cells -- Patient outcomes, B cells -- Comparative analysis, B cells -- Patient outcomes, Lymphocytes -- Histology, Lymphocytes -- Comparative analysis, Lymphocytes -- Patient outcomes, Health
Published
2004

34. Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Author

Moreau, Philippe, primary, Stewart, A Keith, additional, Lazzaro, Antonio, additional, Dimopoulos, Meletios A, additional, Cavo, Michele, additional, Ailawadhi, Sikander, additional, Iskander, Karim, additional, Huang, Mei, additional, Zahlten-Kumeli, Anita, additional, and Mateos, Maria-Victoria, additional

Published
2018
Full Text
View/download PDF

35. Ultrasound-guided central venous catheterization in cancer patients improves the success rate of cannulation and reduces mechanical complications: A prospective observational study of 1,978 consecutive catheterizations

Author

Gorgni Silvia, Mordenti Patrizia, Muroni Monica, Biasini Claudia, Cremona Gabriele, Lazzaro Antonio, Cordani Maria, Bertè Raffaella, Cappucciati Lorella, Di Nunzio Camilla, Vallisa Daniele, Civardi Giuseppe, Cavanna Luigi, Zaffignani Elena, Ambroggi Massimo, Bidin Livia, Palladino Maria, Rodinò Carmelina, and Tibaldi Laura

Subjects
Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background A central venous catheter (CVC) currently represents the most frequently adopted intravenous line for patients undergoing infusional chemotherapy and/or high-dose chemotherapy with hematopoietic stem-cell transplantation and parenteral nutrition. CVC insertion represents a risk for pneumothorax, nerve or arterial punctures. The aim of this prospective observational study was to explore the safety and efficacy of CVC insertion under ultrasound (US) guidance and to confirm its utility in clinical practice in cancer patients. Methods Consecutive adult patients attending the oncology-hematology department were eligible if they had solid or hematologic malignancies and required CVC insertion. Four types of possible complication were defined a priore: mechanical, thrombotic, infection and malfunctioning. The patient was placed in Trendelenburg's position, a 7.5 MHZ puncturing US probe was placed in the supraclavicular site and a 16-gauge needle was advanced under real-time US guidance into the last portion of internal jugular vein. The Seldinger technique was used to place the catheter, which was advanced into the superior vena cava until insertion into right atrium. Within two hours after each procedure, an upright chest X-ray and ultrasound scanning were carried out to confirm the CVC position and to rule out a pneumotorax. CVC-related infections, symptomatic vein thrombosis and malfunctioning were recorded. Results From December 2000 to January 2009, 1,978 CVC insertional procedures were applied to 1,660 consecutive patients. The procedure was performed 580 times in patients with hematologic malignancies and 1,398 times those with solid tumors. A single-needle puncture of the vein was performed on 1,948 of 1,978 procedures (98.48%); only eighteen attempts among 1,978 failed (0.9%). No pneumotorax, no major bleeding, and no nerve puncture were reported; four cases (0.2%) showed self-limiting hematomas. The mean lifespan of CVC was 189.7 +/- 18.6 days (range 7-701). Symptomatic deep-vein thrombosis of the upper limbs developed in 48 patients (2.42%). Catheter-related infections occurred in 197 (9.96%) of the catheters inserted. They were successfully treated with antibiotics and only in 48 (2.9%) patients definitive CVC removal was required for infection and/or thrombosis or malfunctioning. Conclusions This study represents the largest published series of consecutive patients with cancer undergoing CVC insertion under US guidance; this procedure allowed the completion of the therapeutic program for 1,930/1,978 (97.6%) of the catheters inserted. The absence of pneumotorax and other major complications indicates that US guidance should be mandatory for CVC insertion in patients with cancer.

Published
2010
Full Text
View/download PDF

36. Role of image-guided fine-needle aspiration biopsy in the management of patients with splenic metastasis

Author

Civardi Giuseppe, Vallisa Daniele, Lazzaro Antonio, Cavanna Luigi, and Artioli Fabrizio

Subjects
Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Splenic metastases are very rare and are mostly diagnosed at the terminal phase of the disease or at the time of autopsy. The cytohistological diagnosis, when done, is made prevalently by splenectomy. Reports on splenic percutaneous biopsies in the diagnosis of splenic metastasis are fragmentary and very poor. The aims of this study are to analyse retrospectively the accuracy, safety and the clinical impact of ultrasound (US)-guided fine-needle aspiration biopsy (UG-FNAB) in patients with suspected splenic metastasis. Methods A retrospective analysis of 1800 percutaneous abdominal biopsies performed at our institute during the period from 1993 to 2003 was done and 160 patients that underwent splenic biopsy were found. Among these 160 patients, 12 cases with the final diagnosis of solitary splenic metastases were encountered and they form the basis of this report. The biopsies were performed under US guidance using a 22-gauge Chiba needle. All the patients underwent laboratory tests, CT examination of the abdomen and chest, US examination of abdomen and pelvis. Results There were 5 women and 7 men, median age 65 years (range 48–80). Eight patients had a known primary cancer at the time of the diagnosis of splenic metastasis: 3 had breast adenocarcinoma, 2 colon adenocarcinoma, 2 melanoma and 1 lung adenocarcinoma. Four patients were undiagnosed at the time of the appearance of splenic metastasis and subsequent investigations showed adenocarcinoma of the lung in 2 patients and colon adenocarcinoma in the remaining 2. There was a complete correspondence between the US and Computed Tomography (CT) in detecting focal lesions of the spleen. The splenic biopsies allowed a cytological diagnosis of splenic metastasis in all the 12 patients and changed clinical management in all cases. Reviewing the 160 patients that underwent UG-FNAB of the spleen we found no complications related to the biopsies. Conclusion These results indicate that UG-FNAB is a successful technique for diagnosis of splenic metastasis allowing an adequate treatment of the affected patients.

Published
2007
Full Text
View/download PDF

37. Visualization of Fingermarks Deposits on Untreated Thermal Paper Exploiting the Near Infrared Luminescence.

Author

Cappiello, Pietro, Zampa, Francesco, Siciliano, Maria, Amata, Biagio, Di Palma, Renato, Modica, Martino, and Lazzaro, Antonio Pasquale

Subjects
LIGHT sources, LUMINESCENCE, IMAGE processing, THERMOGRAPHIC paper, FORENSIC fingerprinting, INFRARED imaging
Abstract

Thermal paper is widely used as a print medium for different applications but it constitutes a tricky substrate for fingermark visualization. An earlier work (J Forensic Sci 2015;60:1034) reported how to visualize fingermarks on untreated thermal paper by illuminating the item with a UV‐A light source. In the present paper, the potential of the near infrared (NIR) luminescence has been tested on thermal paper compared to the mentioned method. A controlled study was carried out utilizing eccrine enriched fingermarks. The promising outcomes obtained were further confirmed by performing a pseudo‐operational trial. Data clearly showed that the use of the NIR filter gave better results. Finally, preliminary tests suggested a different mechanism of reaction induced by fingermarks with respect to the one behind the thermal printing. Thus, NIR luminescence represents a refinement to the suite of optical examination processes, including the potential to increase the number of marks recovered in a noncontact, nondestructive way. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

38. Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Author

Schjesvold, Fredrik, Dimopoulos, Meletios A., Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Legiec, Wojciech Maciej, Pour, Ludek, Spicka, Ivan, Masszi, Tamas, Doronin, Vadim Anatolievich, Minarik, Jiri, Salogub, Galina, Alexeeva, Yulia, Lazzaro, Antonio, Maisnar, Vladimir, Mikala, Gabor, Norin, Stefan, Thuresson, Marcus, Bergan, Anna, Obermüller, Jakob, Hajek, Roman, Mateos, Maria-Victoria, Richardson, Paul G., and Sonneveld, Pieter

Abstract

Background/Introduction:Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases resulting in rapid release of alkylating agents inside tumor cells. Based on the phase 2 HORIZON study and supported by the phase 3, randomized, controlled OCEAN study, melflufen was approved in Europe for use in patients (pts) with triple-class refractory RRMM with ≥3 prior lines of therapy (LoTs) and without prior autologous stem cell transplantation (ASCT) or with a time to progression (TTP) >36 mo after prior ASCT. In the OCEAN study (NCT03151811), melflufen + dex showed superior progression-free survival (PFS) compared with pom + dex (6.8 vs 4.9 mo; hazard ratio [HR]: 0.79; P=0.032); PFS benefit in the melflufen + dex group was mainly driven by pts who had not received prior ASCT. Overall survival (OS) trended in favor of melflufen + dex in pts without prior ASCT and favored pom + dex in pts with prior ASCT (Schjesvold et al. Lancet Haematol. 2022;9:e98). Post-hoc analyses of OCEAN and HORIZON demonstrated that a TTP <36 mo after prior ASCT was a negative prognostic factor for OS with melflufen + dex (Sonneveld et al. Clin Lymphoma Myeloma Leuk. 2023;S2152). Here, we present long-term OS and safety data from the final analysis of the OCEAN study.

Published
2023
Full Text
View/download PDF

39. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

Author

Moreau, Philippe, primary, Mateos, Maria-Victoria, additional, Berenson, James R, additional, Weisel, Katja, additional, Lazzaro, Antonio, additional, Song, Kevin, additional, Dimopoulos, Meletios A, additional, Huang, Mei, additional, Zahlten-Kumeli, Anita, additional, and Stewart, A Keith, additional

Published
2018
Full Text
View/download PDF

40. Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

Author

Mateos, Maria-Victoria, primary, Moreau, Philippe, additional, Berenson, James R., additional, Weisel, Katja, additional, Lazzaro, Antonio, additional, Song, Kevin W., additional, Dimopoulos, Meletios A., additional, Huang, Mei, additional, Zahlten-Kumeli, Anita, additional, and Stewart, A. Keith, additional

Published
2018
Full Text
View/download PDF

41. Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis

Author

Breccia, Massimo, primary, Tiribelli, Mario, additional, Bonifacio, Massimiliano, additional, Tieghi, Alessia, additional, Polverelli, Nicola, additional, Bergamaschi, Micaela, additional, Cavazzini, Francesco, additional, Cimino, Giuseppe, additional, D'Adda, Mariella, additional, Crugnola, Monica, additional, Bosi, Costanza, additional, Spinsanti, Marco, additional, Molica, Matteo, additional, Fama, Angelo, additional, Andriani, Alessandro, additional, Cerqui, Elisa, additional, Lazzaro, Antonio, additional, Scaffidi, Luigi, additional, Massaro, Fulvio, additional, Latagliata, Roberto, additional, Celesti, Francesca, additional, Lemoli, Roberto massimo, additional, Fanin, Renato, additional, Russo, Domenico, additional, Aversa, Franco, additional, Cuneo, Antonio, additional, Cavo, Michele, additional, Vianelli, Nicola, additional, Alimena, Giuliana, additional, and Palandri, Francesca, additional

Published
2016
Full Text
View/download PDF

42. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens

Author

Bassi, Simona, Stroppa, Elisa M., Moroni, Carlo F., Arbasi, Maria C., Trabacchi, Elena, Di Franco, Anna, Lazzaro, Antonio, Bernuzzi, Patrizia, Moretto, Mauro, Arcari, Annalisa, Bosi, Costanza, Riva, Alessandra, Cavanna, Luigi, and Vallisa, Daniele

Subjects
Adult, Male, Transplantation Conditioning, Filgrastim, Lymphoma, Hematopoietic Stem Cell Transplantation, Middle Aged, Costs and Cost Analysis, Humans, Original Article, Female, Autografts, Multiple Myeloma, Biosimilar Pharmaceuticals, Aged, Retrospective Studies
Abstract

Filgrastim biosimilars have recently been introduced into clinical practice. To date biosimilars have demonstrated comparable efficacy and safety as the originator in chemotherapy-induced neutropenia. Published experience in engraftment after autologous stem cell transplantation (ASCT) is limited and concerns relatively few patients.With the aim of assessing the efficacy and the safety of filgrastim biosimilars in post-ASCT bone marrow recovery, we conducted a single institution, retrospective study in 56 lymphoma and myeloma patients who received filgrastim biosimilars (Tevagrastim(®) and Zarzio(®)) at standard doses from day 5. We compared our results with recently published data on the originator. A cost analysis of each biosimilar was performed.Neutrophil counts recovered in 55 patients. The median number of filgrastim biosimilar vials injected was seven per patient. The median time to neutrophil and platelet recovery was 10 and 12 days, respectively. Twenty-six patients had febrile neutropenia, in half of whom the agent involved was identified. In the cost analysis, the use of Tevagrastim(®) and Zarzio(®) was associated with cost reductions of 56% and of 86%, respectively.Despite differences in CD34+ cell counts and time of starting filgrastim, our results in terms of time to engraftment and median number of vials injected are similar to published data. Comparing our results by single conditioning regimen to recent literature data, the time to engraftment and duration of hospitalisation were equivalent. Significant differences were observed in the incidence of febrile neutropenia, perhaps due to different preventive and prophylactic protocols for infections. Although prospective studies should be performed to confirm our results, filgrastim biosimilars were found to be effective and safe in engraftment after ASCT.

Published
2015

43. Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)

Author

Cavo, Michele, primary, Corradini, Paolo, additional, Di Raimondo, Francesco, additional, Petrini, Mario, additional, Cafro, Anna Maria, additional, Caravita di Toritto, Tommaso, additional, Offidani, Massimo, additional, Semenzato, Gianpietro, additional, Zambello, Renato, additional, Lazzaro, Antonio, additional, Petrucci, Maria Teresa, additional, Rodeghiero, Francesco, additional, Simcock, Mathew, additional, Slaughter, Ana, additional, Herring, Jennifer, additional, Peluso, Teresa, additional, and Palumbo, Antonio, additional

Published
2015
Full Text
View/download PDF

44. Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Author

Brioli, Annamaria, primary, Pezzi, Annalisa, additional, Derudas, Daniele, additional, Petti, Maria Concetta, additional, Zannetti, Beatrice Anna, additional, Ferrara, Felicetto, additional, Rocchi, Serena, additional, Nobile, Francesco, additional, Baraldi, Anna, additional, Musto, Pellegrino, additional, Lanza, Francesco, additional, Mancuso, Katia, additional, Canepa, Letizia, additional, Catalano, Lucio, additional, Lazzaro, Antonio, additional, Pinotti, Graziella, additional, Boccadoro, Mario, additional, and Cavo, Michele, additional

Published
2014
Full Text
View/download PDF

47. Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Author

Sacchi, Stefano, primary, Pozzi, Samantha, additional, Cesaretti, Marina, additional, Marcheselli, Luigi, additional, Buda, Gabriele, additional, Lazzaro, Antonio, additional, Baldini, Luca, additional, Di Raimondo, Francesco, additional, Musto, Pellegrino, additional, Zaccaria, Alfonso, additional, Specchia, Giorgina, additional, Vitolo, Umberto, additional, Magagnoli, Massimo, additional, Silvestris, Franco, additional, Fattori, Pier Paolo, additional, Tosi, Patrizia, additional, Liardo, Eliana Valentina, additional, Bari, Alessia, additional, and Carella, Angelo Michele, additional

Published
2013
Full Text
View/download PDF

48. A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Author

Sacchi, Stefano, primary, Pozzi, Samantha, additional, Badiali, Stefania, additional, Guarini, Attilio, additional, Mazzone, Carla, additional, Corso, Alessandro, additional, Vincelli, Donatella, additional, Masini, Luciano, additional, Musto, Pellegrino, additional, Ria, Roberto, additional, Quarta, Giovanni, additional, Lazzaro, Antonio, additional, Palumbo, Antonio, additional, and Morabito, Fortunato, additional

Published
2012
Full Text
View/download PDF

49. Ten Year-Long Term Survival After up-Front Autologous Stem Cell Transplantation in Multiple Myeloma: Results From Two Prospective Clinical Trials

Author

Zamagni, Elena, primary, Raimondo, Francesco Di, additional, Patriarca, Francesca, additional, Tosi, Patrizia, additional, Pezzi, Annalisa, additional, Cellini, Claudia, additional, Tacchetti, Paola, additional, Ronconi, Sonia, additional, Volpe, Silvestro, additional, Pantani, Lucia, additional, Catalano, Lucio, additional, Fiacchini, Mauro, additional, Angelucci, Emanuele, additional, Masini, Luciano, additional, Gozzetti, Alessandro, additional, Galieni, Piero, additional, Zannetti, Beatrice, additional, Narni, Franco, additional, Brioli, Annamaria, additional, Terragna, Carolina, additional, Lazzaro, Antonio, additional, Mancuso, Katia, additional, Califano, Catello, additional, Ledda, Antonio, additional, Testoni, Nicoletta, additional, Baccarani, Michele, additional, and Cavo, Michele, additional

Published
2012
Full Text
View/download PDF

50. Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Author

Sacchi, Stefano, primary, Pozzi, Samantha, additional, Cesaretti, Marina, additional, Marcheselli, Luigi, additional, Liardo, Eliana Valentina, additional, Buda, Gabriele, additional, Lazzaro, Antonio, additional, Baldini, Luca, additional, Raimondo, Francesco Di, additional, Musto, Pellegrino, additional, Zaccaria, Alfonso, additional, Specchia, Giorgina, additional, Vitolo, Umberto, additional, Magagnoli, Massimo, additional, Silvestris, Franco, additional, Fattori, Pier Paolo, additional, Tosi, Patrizia, additional, and Carella, Angelo Michele, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results